Security
Innoviva, Inc. Common Stock · INVA
INVANASDAQCommon stockCurrentCIK 1080014Updated Oct 28, 2026
Name history
THERAVANCE INC · through Dec 7, 2015ADVANCED MEDICINE INC · through Aug 2, 2000
INVA price & chart
Loading TradingView…
NASDAQ:INVA on TradingView ↗About the company
Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s critical care and infectious disease assets under the IST platform include GIAPREZA® (angiotensin II) for increasing blood pressure in adults with septic or other distributive shock, XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus, XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults, ZEVTERA (ceftobiprole), an advanced-generation cephalosporin antibiotic licensed from Basilea Pharmaceutica International Ltd, Allschwil, and NUZOLVENCE® (zoliflodacin), approved by the …
In the news
No coverage from other publishers is available.
Recent filings
SCHEDULE 13G/A - filed by BlackRock, Inc. regarding Innoviva, Inc.
4 filing
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding Innoviva, Inc.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,429,106,000Source | 1,231,612,000Source | 1,702,727,000Source | 1,333,572,000Source | 1,224,917,000Source | 1,836,587,000Source | 1,254,390,000Source | 1,267,612,000Source | 1,635,165,000Source | 1,301,060,000Source | 1,243,507,000Source | 1,231,497,000Source |
| Property, Plant and Equipment, NetUSD | 1,529,000Source | 544,000Source | 2,133,000Source | 451,000Source | 427,000Source | 2,142,000Source | 483,000Source | 324,000Source | 1,555,000Source | 514,000Source | 483,000Source | 170,000Source |
| GoodwillUSD | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 26,713,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 188,793,000Source | 210,944,000Source | 168,976,000Source | 195,411,000Source | 217,455,000Source | 175,602,000Source | 201,958,000Source | 223,895,000Source | 182,156,000Source | 208,433,000Source | 230,335,000Source | 252,919,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 476,513,000Source | 260,630,000Source | 570,388,000Source | 397,532,000Source | 217,003,000Source | 603,085,000Source | 319,090,000Source | 178,357,000Source | 550,941,000Source | 304,964,000Source | 193,513,000Source | 291,049,000Source |
| Accounts Receivable | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Inventory, NetUSD | 38,363,000Source | 34,236,000Source | 38,968,000Source | 48,996,000Source | 36,664,000Source | 38,843,000Source | 41,479,000Source | 37,437,000Source | 39,172,000Source | 33,725,000Source | 40,737,000Source | 55,897,000Source |
| Assets, CurrentUSD | 684,570,000Source | 400,621,000Source | 753,366,000Source | 651,778,000Source | 358,277,000Source | 772,623,000Source | 582,022,000Source | 311,342,000Source | 727,515,000Source | 554,306,000Source | 344,219,000Source | 443,511,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 19,415,000Source | 12,650,000Source | 24,413,000Source | 16,610,000Source | 8,484,000Source | 24,842,000Source | 15,414,000Source | 16,551,000Source | 26,721,000Source | 21,063,000Source | 21,630,000Source | 29,559,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,402,000Source | 2,789,000Source | 10,377,000Source | 1,759,000Source | 3,118,000Source | 10,652,000Source | 2,110,000Source | 2,269,000Source | 10,929,000Source | 2,453,000Source | 2,536,000Source | 3,265,000Source |
| Other Assets, NoncurrentUSD | 40,961,000Source | 2,800,000Source | 39,894,000Source | 41,178,000Source | 2,982,000Source | 40,527,000Source | 41,269,000Source | 3,112,000Source | 40,744,000Source | 41,477,000Source | 3,267,000Source | 4,299,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 748,000Source | 626,000Source | 727,000Source | 630,000Source | 626,000Source | 738,000Source | 628,000Source | 628,000Source | 747,000Source | 627,000Source | 633,000Source | 692,000Source |
| Retained Earnings (Accumulated Deficit)USD | 105,215,000Source | -22,129,000Source | 372,543,000Source | 15,307,000Source | -23,342,000Source | 455,963,000Source | -48,381,000Source | 11,343,000Source | 269,368,000Source | -1,797,000Source | -25,189,000Source | -204,911,000Source |
| Stockholders' Equity Attributable to ParentUSD | — | — | 1,233,262,000Source | — | — | 1,341,655,000Source | — | — | 1,172,841,000Source | — | — | 565,788,000Source |
| Additional Paid in Capital, Common StockUSD | 903,988,000Source | 690,045,000Source | 859,992,000Source | 698,884,000Source | 688,231,000Source | 884,954,000Source | 694,658,000Source | 1,085,539,000Source | 902,726,000Source | 692,329,000Source | 1,093,340,000Source | 1,163,836,000Source |
| Liabilities and EquityUSD | 1,429,106,000Source | 1,231,612,000Source | 1,702,727,000Source | 1,333,572,000Source | 1,224,917,000Source | 1,836,587,000Source | 1,254,390,000Source | 1,267,612,000Source | 1,635,165,000Source | 1,301,060,000Source | 1,243,507,000Source | 1,231,497,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 48,471,000Source | 223,750,000Source | 47,064,000Source | 246,563,000Source | 28,206,000Source | 36,558,000Source | 234,745,000Source | 29,879,000Source | 49,696,000Source | 236,083,000Source | 38,134,000Source | 134,968,000Source |
| Operating Lease, Liability, CurrentUSD | 680,000Source | 1,511,000Source | 712,000Source | 983,000Source | 1,451,000Source | 646,000Source | 1,280,000Source | 1,268,000Source | 418,000Source | 1,572,000Source | 1,207,000Source | 1,316,000Source |
| Accounts Payable, CurrentUSD | 6,243,000Source | 4,170,000Source | 4,016,000Source | 5,382,000Source | 2,039,000Source | 6,518,000Source | 4,700,000Source | 890,000Source | 4,966,000Source | 2,132,000Source | 6,717,000Source | 2,939,000Source |
| Operating Lease, Liability, NoncurrentUSD | 905,000Source | 1,585,000Source | 10,491,000Source | 1,000,000Source | 1,983,000Source | 10,684,000Source | 1,091,000Source | 1,304,000Source | 10,868,000Source | 1,179,000Source | 1,635,000Source | 2,376,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | 0Source | 36,739,000Source | — | 0Source | 72,831,000Source | — | 3,807,000Source | 31,793,000Source | 0Source | 563,000Source | 5,771,000Source |
| Other Liabilities, NoncurrentUSD | 57,431,000Source | 71,449,000Source | 67,276,000Source | 60,021,000Source | 72,065,000Source | 69,103,000Source | 62,009,000Source | 71,686,000Source | 66,091,000Source | 64,275,000Source | 71,870,000Source | 70,918,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Additional Financial Items | ||||||||||||
| Deferred Revenue, CurrentUSD | 13,571,000Source | 717,000Source | 6,015,000Source | 3,125,000Source | 855,000Source | 3,677,000Source | 1,002,000Source | 987,000Source | 4,270,000Source | 1,126,000Source | 1,277,000Source | 2,094,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 257,377,000Source | 255,972,000Source | 258,454,000Source | 257,019,000Source | 447,282,000Source | 258,095,000Source | 256,670,000Source | 446,759,000Source | 257,731,000Source | 256,316,000Source | 446,234,000Source | 444,180,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | 89,908,000Source | 1,213,000Source | -83,420,000Source | 63,688,000Source | 186,595,000Source | -46,584,000Source | 271,165,000Source | 23,392,000Source | 179,722,000Source | 220,262,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,567,000Source | 2,147,000Source | 9,452,000Source | 6,374,000Source | 5,837,000Source | 7,347,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -961,000Source | -3,719,000Source | 14,574,000Source | 5,938,000Source | 5,053,000Source | 3,525,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 1,310,000Source | 9,153,000Source | 12,919,000Source | 6,808,000Source | 12,004,000Source | -280,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,552,000Source | 2,568,000Source | 2,834,000Source | -4,585,000Source | 3,778,000Source | 92,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 41,038,000Source | -240,000Source | 43,847,000Source | -12,617,000Source | 4,400,000Source | 25,006,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 35,282,000Source | 48,617,000Source | 196,930,000Source | 188,690,000Source | 141,064,000Source | 201,726,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 37,008,000Source | -34,674,000Source | 40,496,000Source | -63,786,000Source | -66,761,000Source | -56,634,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 492,000Source | 0Source | 1,131,000Source | 270,000Source | 411,000Source | 67,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 158,000Source | 67,000Source | 143,000Source | 142,000Source | 77,000Source | 82,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 20,247,000Source | 0Source | 4,532,000Source | 14,777,000Source | 75,728,000Source | 8,503,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -20,146,000Source | 183,000Source | 8,551,000Source | -13,453,000Source | -171,839,000Source | -55,568,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 52,144,000Source | 14,126,000Source | 245,977,000Source | 111,451,000Source | -97,536,000Source | 89,524,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 476,513,000Source | 260,630,000Source | 570,388,000Source | 397,532,000Source | 603,085,000Source | 319,090,000Source | 550,941,000Source | 304,964,000Source | 193,513,000Source | 291,049,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 2,773,000Source | 5,179,000Source | 10,353,000Source | 10,359,000Source | 11,381,000Source | 11,736,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 670,000Source | 0Source | 19,113,000Source | 11,793,000Source | 0Source | 53,855,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,380,000Source | 1,603,000Source | 4,743,000Source | 2,422,000Source | 2,567,000Source | 2,147,000Source | 9,452,000Source | 6,374,000Source | 5,837,000Source | 7,347,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 364,000Source | 541,000Source | 1,887,000Source | 2,110,000Source | 2,065,000Source | 2,055,000Source |
| Amortization of Intangible AssetsUSD | — | — | 6,600,000Source | 6,500,000Source | 6,600,000Source | 6,500,000Source | 6,554,000Source | 6,475,000Source | 26,277,000Source | 25,902,000Source | 21,784,000Source | 5,581,000Source |
| Deconsolidation, Gain (Loss), AmountUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 266,696,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | -20,662,000Source |
| GoodwillUSD | — | — | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 17,905,000Source | 26,713,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | 30,751,000Source | -18,231,000Source | -131,834,000Source | 13,082,000Source | 157,650,000Source | -13,549,000Source | 141,433,000Source | -64,253,000Source | 77,392,000Source | -161,749,000Source |
| Income Tax Expense (Benefit)USD | — | — | 7,909,000Source | 5,636,000Source | -24,600,000Source | 8,910,000Source | 47,968,000Source | 7,995,000Source | 55,697,000Source | 13,996,000Source | 14,376,000Source | 66,687,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 6,341,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 89,908,000Source | 1,213,000Source | -83,420,000Source | 63,688,000Source | 186,595,000Source | -46,584,000Source | 271,165,000Source | 23,392,000Source | 179,722,000Source | 213,921,000Source |
| Operating ExpensesUSD | — | — | 40,961,000Source | 29,770,000Source | 39,761,000Source | 34,395,000Source | 37,679,000Source | 31,887,000Source | 143,922,000Source | — | — | — |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 1,585,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -479,000Source | -914,000Source | -15,000Source | -777,000Source | -366,000Source | -996,000Source | -2,864,000Source | -2,997,000Source | -4,969,000Source | -3,373,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 259,000Source | 250,000Source | 2,553,000Source | 1,466,000Source | 170,000Source | 370,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 107,800,000Source | 89,508,000Source | 119,591,000Source | 100,283,000Source | 97,994,000Source | 88,632,000Source | 411,328,000Source | 358,711,000Source | 310,463,000Source | 331,339,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 27,291,000Source | 26,219,000Source | 34,571,000Source | 26,412,000Source | 32,438,000Source | 27,491,000Source | 113,318,000Source | 115,690,000Source | 98,232,000Source | 63,538,000Source |
| Operating Income (Loss)USD | — | — | 34,578,000Source | 43,237,000Source | 50,855,000Source | 48,751,000Source | 38,154,000Source | 41,428,000Source | 163,745,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | -479,000Source | -914,000Source | -15,000Source | -777,000Source | -366,000Source | -996,000Source | -2,864,000Source | -2,997,000Source | -4,969,000Source | -3,373,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 97,817,000Source | 6,849,000Source | -108,020,000Source | 72,598,000Source | 234,563,000Source | -38,589,000Source | 326,862,000Source | 37,388,000Source | 194,098,000Source | 286,949,000Source |
| Income Tax Expense (Benefit)USD | — | — | 7,909,000Source | 5,636,000Source | -24,600,000Source | 8,910,000Source | 47,968,000Source | 7,995,000Source | 55,697,000Source | 13,996,000Source | 14,376,000Source | 66,687,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 6,341,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 1.3Source | 0.02Source | -1.14Source | 1.01Source | 2.52Source | -0.74Source | 4.02Source | 0.37Source | 2.75Source | 3.07Source |
| Earnings Per Share, DilutedUSD per share | — | — | 1.08Source | 0.02Source | -1.14Source | 0.77Source | 2.22Source | -0.74Source | 3.3Source | 0.36Source | 2.2Source | 2.37Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 69,058,000Source | 62,569,000Source | 73,421,000Source | 62,865,000Source | 74,160,000Source | 62,709,000Source | 67,395,000Source | 62,726,000Source | 65,435,000Source | 69,644,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 84,964,000Source | 62,951,000Source | 73,421,000Source | 84,452,000Source | 84,849,000Source | 62,709,000Source | 84,760,000Source | 74,187,000Source | 86,876,000Source | 95,248,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 6,600,000Source | 6,500,000Source | 6,600,000Source | 6,500,000Source | 6,554,000Source | 6,475,000Source | 26,277,000Source | 25,902,000Source | 21,784,000Source | 5,581,000Source |
| Costs and ExpensesUSD | — | — | — | 82,659,000Source | — | — | — | — | — | 321,323,000Source | 116,365,000Source | 44,390,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 11,850,000Source | 26,613,000Source | 9,976,000Source | 41,286,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Gross ProfitUSD | — | — | 75,539,000Source | 73,007,000Source | 90,616,000Source | 83,146,000Source | 75,833,000Source | 73,315,000Source | 307,667,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 327,060,000Source | — | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | 30,751,000Source | -18,231,000Source | -131,834,000Source | 13,082,000Source | 157,650,000Source | -13,549,000Source | 141,433,000Source | -64,253,000Source | 77,392,000Source | -161,749,000Source |
| Interest ExpenseUSD | — | — | 4,015,000Source | 5,807,000Source | 5,472,000Source | 4,663,000Source | 5,437,000Source | 4,711,000Source | 16,698,000Source | 22,209,000Source | 19,157,000Source | 15,789,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 89,908,000Source | 1,213,000Source | -83,420,000Source | 63,688,000Source | 186,595,000Source | -46,584,000Source | 271,165,000Source | 23,392,000Source | 179,722,000Source | 213,921,000Source |
| Operating ExpensesUSD | — | — | 40,961,000Source | 29,770,000Source | 39,761,000Source | 34,395,000Source | 37,679,000Source | 31,887,000Source | 143,922,000Source | — | — | — |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 1,585,000Source |
| Other IncomeUSD | — | — | — | — | — | — | -215,000Source | 319,000Source | 988,000Source | 724,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 13,670,000Source | 3,551,000Source | 5,190,000Source | 7,983,000Source | 5,241,000Source | 4,396,000Source | 30,604,000Source | 13,654,000Source | 33,922,000Source | 41,432,000Source |
Filing attachments
d228097dex991.htm · 8-K · 2026-08-05
EX-99.1 2 d228097dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress IST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth Royalties portfolio generated $59.8 million in second quarter revenue Launch of wholly-owned Strategic Healthcare Asset, Nortiva Bio, focused on novel extended-release drug delivery technology BURLINGAME, Calif. - Aug 5, 2026 -…
Read attachment ↗d54063dex991.htm · 8-K · 2026-05-06
EX-99.1 2 d54063dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress Generated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth Significant value created across strategic healthcare asset portfolio BURLINGAME, Calif. - May 6, 2026 - Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Comp…
Read attachment ↗inva-ex99_1.htm · 10-K/A · 2026-03-27
Exhibit 99.1 ARMATA PHARMACEUTICALS, INC. INDEX TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS Armata Pharmaceuticals, Inc. Report of Independent Registered Public Accounting Firm (Ernst & Young, LLP; San Diego, CA; PCAOB ID: 42) 2 Consolidated Balance Sheets as of December 31, 2025 and 2024 4 Consolidated Statements of Operations for the Years Ended December 31, 2025 and 2024 5 Consolidated Statements…
Read attachment ↗d23292dex991.htm · 8-K · 2026-02-25
EX-99.1 2 d23292dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth IST product portfolio strengthened with U.S. FDA appro…
Read attachment ↗tm2530226d1_ex99-1.htm · 8-K · 2025-11-05
EX-99.1 2 tm2530226d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress Generated $63.4 million in revenue from durable royalties portfolio IST achieved U.S. net product sales of $29.9 million, representing 52% year-over-year growth Strengthened product portfolio with U.S. launch of ZEVTERA® Announced $125 million share repurchase program BURLINGAME, Calif. - November 5, 2025 - Innoviva, Inc. (NASDAQ: INVA) (“…
Read attachment ↗tm2522376d1_ex99-1.htm · 8-K · 2025-08-06
EX-99.1 2 tm2522376d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress Strong royalties portfolio performance with $67.3 million in revenue IST achieved U.S. net product sales of $29.0 million, reflecting 54% year-over-year growth ZEVTERA (ceftobiprole medocaril sodium, for injection) launched in the U.S. Zoliflodacin NDA accepted by FDA with Priority Review; PDUFA date set for December 15, 2025 BURLINGAME, …
Read attachment ↗